Advertisement
Canada markets open in 49 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    82.26
    -0.47 (-0.57%)
     

  • Bitcoin CAD

    89,675.00
    +4,520.97 (+5.31%)
     

  • CMC Crypto 200

    1,342.34
    +29.72 (+2.32%)
     

  • GOLD FUTURES

    2,398.10
    +0.10 (+0.00%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.5900
    -0.0570 (-1.23%)
     

  • NASDAQ futures

    17,540.75
    -6.50 (-0.04%)
     

  • VOLATILITY

    18.64
    +0.64 (+3.56%)
     

  • FTSE

    7,841.49
    -35.56 (-0.45%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6815
    -0.0006 (-0.09%)
     
MARKETS LIVE BLOG:

STOCK FUTURES DIG OUT OF ISRAEL STRIKE-FUELLED TUMBLE

Shares of Netflix, the first of the megacap techs to report, slide in pre-market trading

The woman behind 'female Viagra' sold her company for $1 billion — then got it back for free

Sarah Berger

In 2015, Cindy Eckert (then Whitehead) made headlines after landing a billion-dollar deal for the company she co-founded, Sprout Pharmaceuticals, which developed female libido-boosting drug Addyi. Eckert co-founded Sprout Pharmaceuticals with her then-husband Robert Whitehead in 2011 to acquire a medication called flibanserin. With it, Sprout developed Addyi, dubbed "female Viagra," to treat hypoactive sexual desire disorder in premenopausal women ( 10 percent of all women suffer from HSDD).

Continue reading